Urology News and Research

Latest Urology News and Research

Serving size in the eye of the beholder

Canadian study findings suggest that many people overestimate the size of one serving of food and may overeat as a result.

2 Aug 2012

Lipid treatment absolved of hemorrhagic transformation guilt

The lipid profiles of patients undergoing thrombolysis for acute stroke predict their mortality risk but not their risk for symptomatic intracerebral hemorrhage, shows a large study.

1 Aug 2012

Obesity also affects sexual and urinary health in men

As a man's waistline grows, so can his experience with sexual dysfunction and frequent urination, say researchers at NewYork-Presbyterian Hospital/Weill Cornell Medical Center. The study, published in the August issue of the British Journal of Urology International (BJUI), is the first to comprehensively show that obesity in men affects not just their hearts and metabolism, but also their sexual and urinary health.

31 Jul 2012

GenSpera receives FDA clearance to commence G-202 Phase II trial in prostate cancer

GenSpera, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared for initiation a Phase II human clinical trial of its lead compound, G-202, in the treatment of prostate cancer patients who have failed prior hormonal therapy.

31 Jul 2012

Smoking poses less risk for dyslipidemia in very elderly

Smoking does not have a detrimental effect on lipid profiles in individuals aged 90 years or more, report Chinese researchers.

31 Jul 2012

Men with large waists urinate more frequently than their slimmer counterparts

Men with large waists urinate more frequently than their slimmer counterparts, according to research in the August issue of the urology journal BJUI.

31 Jul 2012

Researchers identify link between complete kidney removal and erectile dysfunction

Researchers at the University of California, San Diego School of Medicine have identified a link between patients who undergo total nephrectomy - complete kidney removal - and erectile dysfunction.

31 Jul 2012

Watson seeks FDA approval to market Epiduo Gel for severe acne

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration seeking approval to market Epiduo (adapalene and benzoyl peroxide) Gel, 0.1% / 2.5%.

30 Jul 2012

Paper highlights clinical and immunological activity of immatics’ IMA901 in renal cell carcinoma

immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that key data covering the scientific and clinical development of its lead cancer vaccine, IMA901, have been published in Nature Medicine.

30 Jul 2012

Brown fat fuels fight against obesity

Experts may have found a new method for assessing adipose tissue function that could be used in the fight against obesity.

26 Jul 2012

Virginia Hospital Center offers new Calypso System for patients with prostate cancer

Virginia Hospital Center is among the few hospitals along the east coast to offer the new Calypso® System featuring GPS for the Body technology and Beacon electromagnetic transponders for patients with certain types of cancer.

26 Jul 2012

Bard completes enrollment in Lutonix DCB clinical trial for peripheral arterial disease

C. R. Bard, Inc. today announced that its Lutonix technology center completed patient enrollment into its global, multicenter LEVANT 2 randomized clinical trial.

26 Jul 2012

Miriam researchers encourage physicians to inquire about ED symptoms in young, middle-aged men

Although erectile dysfunction (ED) has been shown to be an early warning sign for heart disease, some physicians - and patients - still think of it as just as a natural part of "old age." But now an international team of researchers, led by physicians at The Miriam Hospital, say it's time to expand ED symptom screening to include younger and middle-aged men.

26 Jul 2012

Healthcare system perceptions predict PSA screening uptake

Study findings suggest that African–American and Afro–Caribbean men who have poor perceptions or experiences of their healthcare system are less likely to have prostate-specific antigen screening than those with positive healthcare experiences.

25 Jul 2012

Bayer, Onyx and Astellas announce results from Tarceva plus Nexavar Phase 3 trial on HCC

Bayer HealthCare Pharmaceuticals, Onyx Pharmaceuticals, Inc., and Astellas Pharma Inc. today announced that a Phase 3 trial evaluating the efficacy and safety of the addition of Tarceva (erlotinib) tablets to Nexavar (sorafenib) tablets did not improve overall survival for patients with unresectable hepatocellular carcinoma (HCC) vs. Nexavar alone.

23 Jul 2012